New Drug: Cosibelimab for Cutaneous SCC

  • Study

    Open-label multicenter, phase I trial (NCT03212404)
    Metastatic or locally advanced cutaneous SCC
    Cosibelimab 800 mg q2wks (n=78)

  • Efficacy

    ORR: 47.4%
    mDoR: Not reached

  • Safety

    Fatigue (26.9%), rash (16.7%), and anemia (15.4%)


    • J Immunother Cancer 2023 Oct;11(10):e007637

    Clingan P,Ladwa R,Brungs D Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

    http://doi.org/10.1136/jitc-2023-007637

    Reviewed by Ulas D. Bayraktar, MD on Dec 16, 2024

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag